

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/867,034	05/29/2001	Roberto A. Macina	DEX-0207	5629	
26259 7	590 04/09/2003				
LICATLA & TYRRELL P.C.			EXAMINER		
66 E. MAIN STREET			YU, MISOOK		
MARLTON, N	IJ 08053				
			ART UNIT	PAPER NUMBER	
			1642	10	
			DATE MAILED: 04/09/2003	(>	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Advisory Action	09/867,034	MACINA ET AL.	
Advisory Adden	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	
The MAILING DATE of this communication appe	ars n the cover sheet with the c	orrespondence address	
THE REPLY FILED 06 March 2002 FAILS TO PLACE TO Therefore, further action by the applicant is required to available final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica) a timely filed amendment which	ation. A proper reply to a	
PERIOD FOR RE	EPLY [check either a) or b)]		
a) The period for reply expires <u>3</u> months from the mailing date			
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officianely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officianely filed, may reduce any earned patent term adjustment.	ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH date on which the petition under 37 CFI of extension and the corresponding amo the shortened statutory period for reply ce later than three months after the mail	g date of the final rejection. IE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extens unt of the fee. The appropriate extens originally set in the final Office action;	sion sion
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF	R 1.191(d)), to avoid dismissal of		
2. The proposed amendment(s) will not be entered be	ecause:		
(a) they raise new issues that would require further	•	see NOTE below);	
(b) they raise the issue of new matter (see Note b	elow);		
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying th	e
(d) they present additional claims without canceli NOTE:	ng a corresponding number of fi	nally rejected claims.	
3. Applicant's reply has overcome the following rejecti	on(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendmen	ıt
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: Sec		dered but does NOT place the	
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly	
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: <u>15</u> .			
Claim(s) objected to:			
Claim(s) rejected: 1.			
Claim(s) withdrawn from consideration:			
8. The proposed drawing correction filed on is	a)□ approved or b)□ disapp	roved by the Examiner.	
9. Note the attached Information Disclosure Statemer	nt(s)(PTO-1449) Paper No(s)	·	
10. Other:			
		Misook Yu, 3/25/2003	

3 .3

Continuation of 5. does NOT place the application in condition for allowance because: the amended claim 1 in the after-final amendment is still drawn to nucleic acids variants of SEQ ID NO:5. Applicant argues that the invention relates to nucleic acid sequences over expressed in colon cancer. This argument is not persuasive because the argument is not commensurate in scope of claims, drawn to any nucleic acids with 97 % identity. Applicant further argues that the limitations "97 % sequence identity" and "capable of hybridizing" give enough written description for what is being claimed is not persuaive either because the Office interprets the limitations as the other variants such as alleleic variants and splicing variants that the instant specification does not describe and further the specification does not describe what biological activity is being associated with the nucleic acid with 97 % identity to SEQ ID NO:5.

MARY E. MOSHER PRIMARY EXAMINER GROUP 1800

1600

PRIMARY EXAMIN GROUP 1800